Research Conducted at University of Pennsylvania Has Provided New Information about Immunotherapy (B7-H4 as a potential target for immunotherapy for gynecologic cancers: A closer look)
By a News Reporter-Staff News Editor at Cancer Weekly -- Researchers detail new data in Biotechnology. According to news reporting out of Philadelphia, Pennsylvania, by NewsRx editors, research stated, "B7-H4 is a transmembrane protein that binds an unknown receptor on activated T cells resulting in inhibition of T-cell effector function via cell cycle arrest, decreased proliferation, and reduced IL-2 production. B7-H4 is up-regulated on the surface of cancer cells and immunosuppressive tumor-associated macrophages (TAMs) in a variety of human cancers."
Our news journalists obtained a quote from the research from the University of Pennsylvania, "Notably, B7-H4 expression levels inversely correlate with patient survival in ovarian cancer, making B7-H4 an attractive candidate for therapeutic intervention. Here, we summarize the experimental data and methodologies that have revealed B7-H4's mRNA and protein expression and function in both mice and humans since its discovery in 2003, with a specific focus on B7-H4's role in ovarian cancer. We also underscore the discrepancies in published data due to high variability in methodology and use of different antibodies, most of which are not commercially available. Finally, since B7-H4 is expressed on tumor cells and TAMs in various cancer types, directing therapeutics against B7-H4 could have tremendous synergistic outcomes in favorably altering the tumor micro-environment and eliminating cancer cells."
According to the news editors, the research concluded: "We highlight the therapeutic potential of targeting B7-H4, both by comparing other negative immune modulators such as PD-1 and CTLA-4 and by identifying novel methods to target B7-H4 directly or indirectly to overcome B7-H4-mediated T-cell inhibition."
For more information on this research see: B7-H4 as a potential target for immunotherapy for gynecologic cancers: A closer look. Gynecologic Oncology, 2014;134(1):181-189. Gynecologic Oncology can be contacted at: Academic Press Inc Elsevier Science, 525 B St, Ste 1900, San Diego, CA 92101-4495, USA. (Elsevier - www.elsevier.com; Gynecologic Oncology - www.elsevier.com/wps/product/cws_home/622840)
Our news journalists report that additional information may be obtained by contacting J.B. Smith, University of Pennsylvania, Ovarian Canc Res Center, Dept. of Pathol & Lab Med, Abramson Canc CenterPerelman Sch Med, Philadelphia, PA 19104, United States. Additional authors for this research include C. Stashwick and D.J. Powell (see also Biotechnology).
Keywords for this news article include: Biotechnology, Cancer, Oncology, Gynecology, Philadelphia, Pennsylvania, United States, Immunotherapy, Immunomodulation, North and Central America
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC